S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

IMTX Immatics NV

10.77

-0.12 (-1.10%)

04 May 2024 - Closed

Delayed by 15 minutes

Immatics shares jump after early-stage Adoptive Cell Therapy cancer study data

To read the full story on Seeking Alpha, click here.

Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Immatics NV Charts.

Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Immatics NV Charts.

Immatics NV News

Immatics Announces Full Year 2023 Financial Results and Corporate Update
Thursday 21 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 23 January 2024 (3 months ago) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Saturday 20 January 2024 (4 months ago) • Edgar (US Regulatory)

Immatics Announces Pricing of $175 Million Public Offering
Thursday 18 January 2024 (4 months ago) • GlobeNewswire Inc.

Form 424B5 - Prospectus [Rule 424(b)(5)]
Thursday 18 January 2024 (4 months ago) • Edgar (US Regulatory)

Immatics Announces Proposed Public Offering
Thursday 18 January 2024 (4 months ago) • GlobeNewswire Inc.

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
Tuesday 16 January 2024 (4 months ago) • PR Newswire (US)

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
Tuesday 16 January 2024 (4 months ago) • PR Newswire (US)

Levicept Appoints Eliot Forster as CEO
Thursday 30 November 2023 (5 months ago) • GlobeNewswire Inc.

Immatics Announces Third Quarter 2023 Financial Results and Business Update
Tuesday 14 November 2023 (6 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 8 November 2023 (6 months ago) • Edgar (US Regulatory)

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
Wednesday 8 November 2023 (6 months ago) • GlobeNewswire Inc.

More Immatics NV News Articles

Gold vs US Dollar

Invesco QQQ Trust Series 1

AUD vs US Dollar

Newcrest Mining

Westpac Banking

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions